Mizuho Reiterates Buy Rating on uniQure N.V. (QURE)
Mizuho maintains a buy rating on uniQure with a $68 price target, a 43.13% upside from the current price.
Key Points
- Mizuho reiterated its buy rating on uniQure N.V. (QURE) with a $68 price target on June 25, 2026.
- Mizuho's $68 price target implies 43.13% upside from uniQure N.V.'s ($QURE) current $47.51 share price.
- uniQure's stock traded near $49.61 on Thursday, with a market cap of around $2.8 billion and a forward P/E ratio not meaningful due to negative earnings.
- Peers like Aberdeen Group and Two Sigma Investments increased their holdings, while others like Avoro Capital Advisors reduced theirs.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho reiterated its buy rating on uniQure N.V. (NasdaqGS:QURE) on June 25, 2026, setting a price target of $68. Shares of uniQure traded near $49.61 on Thursday.
Mizuho vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Mizuho's uniQure Position
Mizuho's analyst Uy Ear maintained their positive outlook on uniQure, reiterating a buy rating and setting a price target of $68. This suggests confidence in the company's prospects despite the lack of a prior target comparison.
Other Institutional Activity in uniQure
Several institutional investors have been active in uniQure. Aberdeen Group PLC increased its holdings by 1,627,746 shares, bringing its total to about 5.3 million shares worth approximately $86.8 million, marking a 44.2% increase. Two Sigma Investments, LP also boosted its stake by 1,224,587 shares to a total of around 2.7 million shares, valued at roughly $43.8 million, an 84.4% increase. In contrast, Avoro Capital Advisors LLC reduced its position by 190,405 shares, now holding roughly 5.9 million shares valued at about $97.4 million, a 3.1% decrease.
uniQure N.V. Stock Down 2.5%
On Thursday, uniQure shares traded near $49.61. The company, with a market cap of approximately $2.8 billion, operates in the biotechnology industry. Despite negative earnings, reflected in a forward P/E ratio of -14.96, the stock has shown volatility with a 52-week range between $8.73 and $71.5. It has a beta of 1.001, indicating market-like volatility, and its financial stability is supported by a current ratio of 10.40.
$QURE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, Mizuho maintained its buy rating on uniQure with a $68 price target. Earlier in June, Barclays upgraded the stock to a buy rating, setting a target of $65. Goldman Sachs maintained a hold rating with a $46 target, while Leerink Partners and RBC Capital both maintained their buy ratings with price targets of $70 and $65, respectively. The consensus among 11 analysts is a strong buy, with an average target price of $58.57.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands. It focuses on developing gene therapies for rare and serious diseases. Its flagship product, HEMGENIX, helps hemophilia B patients reduce bleeding risks. The company is also working on treatments for Huntington's disease and other conditions, with several candidates in clinical trials. Led by CEO Matthew Kapusta, uniQure employs over 220 people.
Bottom Line
Mizuho's reiterated buy rating on uniQure N.V. underscores the firm's confidence in the company's future potential. Investors watch these ratings closely, as they can influence market sentiment and investment decisions. It's important to remember that analyst ratings and targets are based on past and current data, and investors should consider them as part of a broader investment strategy.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.